<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">Hepatic venoocclusive disease</z:e> (HVOD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) and is a well-recognized dose-limiting toxicity of oral <z:chebi fb="0" ids="28901">busulfan</z:chebi> (Bu)-based preparative regimens </plain></SENT>
<SENT sid="1" pm="."><plain>The unpredictable absorption of oral Bu from the gastrointestinal (GI) tract and hepatic first-pass effects have led to the development of an intravenous Bu preparation (i.v </plain></SENT>
<SENT sid="2" pm="."><plain>Bu) </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this retrospective comparison was to evaluate the incidence rate of HVOD and the 100-day mortality rate in patients treated with a <z:chebi fb="0" ids="28901">busulfan</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (BuCy2) regimen in which either oral Bu or i.v </plain></SENT>
<SENT sid="4" pm="."><plain>Bu was administered </plain></SENT>
<SENT sid="5" pm="."><plain>Data from 2 similar groups of patients treated between March 1995 and December 1997 were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>Thirty patients were treated with oral Bu (1 mg/kg x 16 doses) at City of Hope and 61 patients were treated with i.v </plain></SENT>
<SENT sid="7" pm="."><plain>Bu (0.8 mg/kg x 16 doses) in a multicenter trial involving 7 sites </plain></SENT>
<SENT sid="8" pm="."><plain>Bu was followed by Cy (60 mg/kg x 2 days) and a histocompatible-sibling-donor HSCT </plain></SENT>
<SENT sid="9" pm="."><plain>In the i.v </plain></SENT>
<SENT sid="10" pm="."><plain>Bu treatment group, 48% of the patients were classified as heavily pretreated (&gt; or = 3 prior chemotherapy regimens, prior radiation, or prior HSCT) with 13% having had a prior HSCT and 75% having active disease at the time of transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>According to the same classification criteria, 33% of the patients in the oral-Bu treatment group were considered heavily pretreated, with 23% having had a prior HSCT and 80% having active disease at the time of transplantation </plain></SENT>
<SENT sid="12" pm="."><plain>The incidence rates of clinically diagnosed HVOD were 5/61 (8%) and 10/30 (33%) after i.v. and oral Bu, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>HVOD-related mortality occurred in 2 (3.3%) of 61 i.v. and 6 (20%) of 30 oral Bu patients </plain></SENT>
<SENT sid="14" pm="."><plain>The (standardized) Jones criteria for HVOD were met by 4.9% of i.v. and 20% of oral Bu patients </plain></SENT>
<SENT sid="15" pm="."><plain>Univariate logistic regression analysis identified oral versus i.v </plain></SENT>
<SENT sid="16" pm="."><plain>Bu (P = .001) and a diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (P = .04) as statistically significant factors in the development of HVOD, with prior extensive treatment identified as marginally significant (P = .25) </plain></SENT>
<SENT sid="17" pm="."><plain>No other demographic parameter was found to be significant </plain></SENT>
<SENT sid="18" pm="."><plain>After adjustment for prior treatment, multivariate analyses showed that the use of oral versus i.v </plain></SENT>
<SENT sid="19" pm="."><plain>Bu was the strongest predictor for development of HVOD (odds ratio, 7.5; 95% confidence interval, 2.1-27.2; P = .002) </plain></SENT>
<SENT sid="20" pm="."><plain>This study showed that the incidence rate of HVOD is significantly lower (P = .002) and the 100-day survival rate significantly higher (P = .002) in patients treated with i.v </plain></SENT>
<SENT sid="21" pm="."><plain>Bu than in patients treated with oral Bu when Bu is used as part of a BuCy2 preparative regimen for allogeneic HSCT </plain></SENT>
</text></document>